Germany And Netherlands Medical Marijuana Market To Reach $299.4 Million By 2030

Germany And Netherlands Medical Marijuana Market Growth & Trends

The Germany and Netherlands medical marijuana market size is expected to reach USD 299.4 million in 2030 and is projected to grow at a CAGR of 25.3% from 2025 to 2030. The growing adoption of marijuana for the treatment of chronic diseases is positively impacting the growth. Furthermore, increasing its legalization and use for therapeutic purposes is further bolstering revenue growth over the forecast period.

Based on the product, the flower segment dominated the market in 2019. Flowers are generally utilized for smoking purposes and have applications in a variety of health-related conditions such as in the treatment of glaucoma and nausea. Such factors are contributing to the increase in demand for the flower. In addition, rapid onset of action with respect to the smoking of flowers and its applications in alleviating chronic pain, reducing cancer, stopping the progression of Alzheimer’s disease is further propelling the market growth.

In 2019, the chronic pain segment accounted for the highest revenue share. This growth is attributed to the presence of legal programs in both the countries and its increasing acceptance for various chronic conditions. In addition, scientific literature supporting its benefits in the treatment of various diseases, including chronic pain is further fueling the growth.

Germany dominated the market with a revenue share of 98.0% in 2019 owing to the increasing population and high demand for medical use. Furthermore, liberal government regulations, sanctioning of cultivation licenses in the country, and its legalization for health-related or therapeutic purposes are boosting the growth of the market in the country.

 Request a free sample copy or view report summary: Germany And Netherlands Medical Marijuana Market Report

Germany And Netherlands Medical Marijuana Market Report Highlights

• Increasing adoption of marijuana for the treatment of chronic diseases and its legalization to be used for therapeutic purposes is driving the market

• Oil products dominated the market and accounted for the largest revenue share of 55.3% in 2024. This growth is attributed to established clear regulations by both countries that facilitate the production and distribution of cannabis oil, making it more accessible to patients.

• The chronic pain segment dominated the market in 2024, owing to the presence of legal programs in both the countries and increasing acceptance of medical marijuana to treat various chronic conditions.

• The Netherlands medical marijuana market dominated the market and accounted for the largest revenue share of 91.2% in 2024. This growth is attributed to its long-standing history of cannabis use and progressive regulatory framework.

Germany And Netherlands Medical Marijuana Market Segmentation

Grand View Research has segmented the Germany and Netherlands medical marijuana market based on product, application, and country:

Germany And Netherlands Medical Marijuana Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Flower

• Oil

Germany And Netherlands Medical Marijuana Application Outlook (Revenue, USD Million, 2018 - 2030)

• Chronic Pain

• Mental Disorders

Germany And Netherlands Medical Marijuana Country Outlook (Revenue, USD Million, 2018 - 2030)

• Germany

• Netherlands

List of Key Players in Germany And Netherlands Medical Marijuana Market

• ADREXpharma GmbH

• Canopy Growth Corporation

• Aphria, Inc

• Aurora Cannabis

• Tilray

• GW Pharmaceuticals, plc

• Organigram Holdings, Inc

• The Cronos Group

• Demecan GmbH

• Cannamedical Pharma GmbH